Cronos (CRON) 6-K Cronos Group and Ginkgo Bioworks Announce a Landmark Partnership to Produce Cultured Cannabinoids

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuantto Section 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of: September, 2018

Commission FileNumber: 001-38403

CRONOS GROUP INC.

(Name of registrant)

720 King Street W., Suite 320

Toronto, Ontario

M5V 2T3

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover ofForm 20-F orForm 40-F:

Form20-F   ☐            Form 40-F  ☒

Indicate by check mark if the registrant is submitting theForm 6-K in paper as permitted byRegulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting theForm 6-K in paper as permitted byRegulation S-T Rule 101(b)(7):  ☐

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CRONOS GROUP INC.
Date: September 4, 2018	By:	/s/ Michael Gorenstein
	Name:	Michael Gorenstein
	Title:	President and Chief Executive Officer

EXHIBIT INDEX

Exhibit	Description of Exhibit
99.1	News release dated September 4, 2018 – “Cronos Group and Ginkgo Bioworks Announce a Landmark Partnership to Produce Cultured Cannabinoids”
99.2	The material change report of Cronos Group Inc. dated September 4, 2018 in respect of the announcement of the collaboration and license agreement with Ginkgo Bioworks, Inc.
99.3	Collaboration and License Agreement, dated as of September 1, 2018, by and between Ginkgo Bioworks, Inc. and Cronos Group Inc.